Metagenomi Inc
Company Profile
Business description
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Contact
5959 Horton Street
7th Floor
EmeryvilleCA94608
USAT: +1 510 871-4880
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
176
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,676.65 | 88.46 | -1.14% |
| DAX 40 | 23,459.64 | 311.81 | -1.31% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,835.01 | 49.91 | -0.56% |
| HKSE | 23,833.17 | 202.21 | -0.84% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,377.00 | 25.66 | -0.75% |